|
|
EN

  • 業務谘詢

    中國：

    Email: marketing@yakkaa.com

    業務谘詢專線：400-780-8018

    （僅限服務谘詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心
Jul 05,2023
設計合成一種高度選擇性的H435R突變敏感的甲狀腺激素受體β激動劑，PK分析通過hjc黄金城進行
Thyroid hormone receptors (TRs) are ligand-dependent transcription factors that belong to the nuclear receptor superfamily and also participate in important physiological functions. In this study, Compound 16g is a well-characterized selective and mutation-sensitive TRβ agonist for further investigating its function in treating dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH). Compound 16g showed excellent lipid metabolism, safety, metabolic stability, and pharmacokinetic properties. PK properties of Compound 16g were analyzed by Medicilon.
查看更多
設計合成一種高度選擇性的H435R突變敏感的甲狀腺激素受體β激動劑，PK分析通過hjc黄金城進行
Jul 05,2023
研究人員設計合成STAT3和HDAC雙通路抑製劑用於治療實體腫瘤，PK實驗通過hjc黄金城進行
The inhibition of HDACs will lead to compensated activation of a notorious cancer-related drug target, STAT3, in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. Herein, researchers synthesized a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity. The pharmacokinetic experiment in SD Rats was carried out by Medicilon.
查看更多
研究人員設計合成STAT3和HDAC雙通路抑製劑用於治療實體腫瘤，PK實驗通過hjc黄金城進行
Jul 05,2023
阿帕替尼通過VEGFR2通路抑製紫杉醇對胃癌細胞的耐藥性
Overexpression of VEGFR2 can offset the rescue effect of Apatinib on Paclitaxel-induced drug resistance of MGC803 cells. Apatinib inhibits Paclitaxel resistance of MGC803 cells via the VEGFR2 signaling pathway. In this research, the VEGFR2 sequences were designed and then amplified by RT-PCR. The sequences were then ligated with a pcDNA3.0 plasmid to construct a recombinant pcDNA3.0-VEGFR2 vector (Medicilon).
查看更多
阿帕替尼通過VEGFR2通路抑製紫杉醇對胃癌細胞的耐藥性
Jul 05,2023
研究人員報告了一種具有細胞滲透性的選擇性METTL3納摩爾抑製劑UZH1a，作者感謝hjc黄金城合成了UZH1a和UZH1b
The methylase METTL3 is the writer enzyme of the N6‐methyladenosine (m6A) modification of RNA. Here researchers report a nanomolar inhibitor of METTL3 (UZH1a) which is selective and cell‐permeable, while its enantiomer UZH1b is essentially inactive. The s thank Medicilon for the synthesis of the UZH1a and UZH1b compounds.
查看更多
研究人員報告了一種具有細胞滲透性的選擇性METTL3納摩爾抑製劑UZH1a，作者感謝hjc黄金城合成了UZH1a和UZH1b
Jul 05,2023
研究人員設計並合成了一種光籠PI3K抑製劑1，它可以通過紫外線照射激活，釋放出高效PI3K抑製劑2。化合物1和2的ADME研究通過hjc黄金城進行
Aberrant activation of the PI3K pathway has been intensively targeted for cancer therapeutics for decades. In this work, researchers designed and synthesized a novel photocaged PI3K inhibitor 1, which could be readily activated by UV irradiation to release a highly potent PI3K inhibitor 2. ADME studies of compounds 1 and 2 were conducted by Medicilon. Medicilon's pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody.
查看更多
研究人員設計並合成了一種光籠PI3K抑製劑1，它可以通過紫外線照射激活，釋放出高效PI3K抑製劑2。化合物1和2的ADME研究通過hjc黄金城進行
Jul 05,2023
RIPK2激酶參與多種慢性炎症，UH15-15抑製RIPK2激酶並具有良好的體外ADME和PK特性，PK研究通過hjc黄金城進行
Receptor interacting protein kinase-2 (RIPK2) is an enzyme involved in the transduction of pro-inflammatory nucleotide-binding oligomerization domain cell signaling, a pathway implicated in numerous chronic inflammatory conditions. UH15-15 inhibits RIPK2 kinase (IC50=8 nM) and demonstrates favorable in vitro ADME and pharmacokinetic properties. The pharmacokinetic study was conducted by Medicilon.
查看更多
RIPK2激酶參與多種慢性炎症，UH15-15抑製RIPK2激酶並具有良好的體外ADME和PK特性，PK研究通過hjc黄金城進行
Jul 05,2023
合成具有體內抗腫瘤活性的強效PD-L1抑製劑，並進行生物學評價和機製研究。PK研究通過hjc黄金城進行
PD-1 and PD-L1 have been very successful for the treatment of various tumors, including NSCLC, urothelial cancer, melanoma, head and neck squamous cell cancer, and lymphoma. Researchers identified compound L7 as a potent PD-L1 inhibitor that blocked PD-1/PD-L1 interaction. Pharmacokinetic (PK) studies demonstrated that L7 was orally bioavailable. PK studies were conducted by Medicilon.
查看更多
合成具有體內抗腫瘤活性的強效PD-L1抑製劑，並進行生物學評價和機製研究。PK研究通過hjc黄金城進行
Jul 05,2023
SLL-1206是一種κ阿片受體激動劑，具有顯著改善的理化和藥代動力學特性。作者感謝hjc黄金城對SLL-1206進行的藥代動力學研究
The search for selective kappa opioid receptor (κOR) agonists with an improved safety profile is an area of interest in opioid research. SLL-1206 is a κOR agonist with single-digit nanomolar activities. SLL-1206 exhibits substantially improved physicochemical and pharmacokinetic properties, and reduces central nervous system effects. The s are grateful to Medicilon Preclinical Research LLC. for pharmacokinetic studies on SLL-1206.
查看更多
SLL-1206是一種κ阿片受體激動劑，具有顯著改善的理化和藥代動力學特性。作者感謝hjc黄金城對SLL-1206進行的藥代動力學研究
Jul 05,2023
苯並咪唑衍生物XY123是一種口服有效的選擇性RORγ反向激動劑。在本研究中，所有肝微粒體測定均通過hjc黄金城進行
Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. XY123 potently inhibits the RORγ transcription activity with an IC50 value of 64 nM. XY123 demonstrates good metabolic stability and a pharmacokinetics property with reasonable oral bioavailability (32.41%) and moderate half-life (4.98 h). All liver microsome assays were performed by Medicilon.
查看更多
苯並咪唑衍生物XY123是一種口服有效的選擇性RORγ反向激動劑。在本研究中，所有肝微粒體測定均通過hjc黄金城進行
Jul 05,2023
zapERtrap：光調節的內質網釋放係統揭示了意想不到的神經元運輸途徑，Zapalog的合成通過hjc黄金城進行
zapERtrap opens the door to previously unapproachable questions concerning how proteins are processed, trafficked, and secreted in space and time in complex cellular environments. zapERtrap relies on a small-molecule protein dimerizer zapalog, which consists of the antibiotic trimethoprim tethered to a synthetic ligand of FK506-binding protein through a photocleavable linker. Synthesis of zapalog was performed by Medicilon.
查看更多
zapERtrap：光調節的內質網釋放係統揭示了意想不到的神經元運輸途徑，Zapalog的合成通過hjc黄金城進行